Have a Question?
You can pose a question to the speaker by clicking on the "
" icon at the end of the session title. Appropriate questions will be answered during the session as time permits (not all questions will be answered).
Over the past 10 years – or more – both pharmaceutical and biotech companies have outsourced or off-shored operations to a diverse range of geographic locations. The prevalent locales, India and China were initially viewed as sources of lower cost materials, labor or manufacturing operations. As the populations in these countries grow they are providing markets for products that are in decline in the traditional markets. However, there are as many issues as opportunities - in particular the BRIC (Brazil, Russia, India and China) countries have a lot of challenges. US and European companies are expanding operations into Brazil in particular - however there are many issues - not the least of which relates to infrastructure - roads, harbors, customs and import restrictions etc. And then of course there are issues in the chain of custody - cold chain is a major problem in emerging markets, particularly in biotech and vaccine distribution. And then there is the growing concern related to counterfeit, piracy and product diversion. This presentation will review the challenges as well as outlining an approach to establish a balance between risk and reward in emerging markets.
|Risk or Reward ' Exploring the Challenges of Manufacturing and Distribution Operations in Emerging Markets |
Room: 1E16 ~ 2:00 pm - 3:30 pm (Wednesday, March 30, 2011)